In a nonrandomized study (NLM, NCT00882921) for evaluation of the idursulfase long-term ERT for mucopolysaccharidosis II patients, it was found that 50% of the patients presented idursulfase-specific IgG antibodies (Giugliani et al., 2017). The gene discussed is IDS; the disease is mucopolysaccharidosis type 2.